EU Clinical Trials Register

Clinical trial results:
A Single arm, Open-Label, Phase 4 Study Evaluating QT Interval, Pharmacokinetics, and Safety of Gemtuzumab Ozogamicin (Mylotarg) as a Single-Agent Regimen in Subjects With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.

Summary

EudraCT number	2018-002619-89
Trial protocol	DE GB HU PL ES
Global end of trial date	27 April 2021

Results information

Result version number	v1 (current)
This version publication date	10 November 2021
First version publication date	10 November 2021

Trial information

Trial identification

Sponsor protocol code	B1761031

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03727750
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 August 2021
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	27 April 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:	
To assessed the effect of GO on the QTc interval.	
Protection of trial subjects:	
The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.	
Background therapy: -	
Evidence for comparator: -	
Actual start date of recruitment	03 July 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 5
Country: Number of subjects enrolled	Hungary: 7
Country: Number of subjects enrolled	Poland: 12
Country: Number of subjects enrolled	Spain: 14
Country: Number of subjects enrolled	United Kingdom: 6
Country: Number of subjects enrolled	United States: 7
Worldwide total number of subjects	51
EEA total number of subjects	33

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	19
From 65 to 84 years	32
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study was conducted in 6 countries from 03 July 2019 to 27 April 2021. A total of 51 subjects were enrolled.

Pre-assignment

Screening details:

Total 66 subjects signed the informed consent form and were screened. From the 66 subjects, 51 subjects were enrolled in the study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Gemtuzumab Ozogamicin (GO)

Arm description:

Subjects with confirmed diagnosis of refractory or relapsed cluster of differentiation (CD33)- positive Acute Myeloid Leukemia (AML) aged greater than or equal to (>=) 18 years received three doses of Gemtuzumab Ozogamicin, 3 milligram per meter square (mg/m^2) as intravenous (IV) infusion on Days 1, 4 and 7 of Cycle 1 and 2.

Arm type	Experimental
Investigational medicinal product name	Gemtuzumab Ozogamicin
Investigational medicinal product code	CMA-676
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received three doses of gemtuzumab ozogamicin as IV infusion on Days 1, 4 and 7 of Cycle 1 and 2.

Number of subjects in period 1	Gemtuzumab Ozogamicin (GO)
Started	51
Completed	2
Not completed	49
Adverse event, serious fatal	45
Consent withdrawn by subject	2
Unspecified	1
Lost to follow-up	1

Baseline characteristics

Reporting groups

Reporting group title	Gemtuzumab Ozogamicin (GO)
Reporting group description:	

Subjects with confirmed diagnosis of refractory or relapsed cluster of differentiation (CD33)- positive Acute Myeloid Leukemia (AML) aged greater than or equal to (>=) 18 years received three doses of Gemtuzumab Ozogamicin, 3 milligram per meter square (mg/m^2) as intravenous (IV) infusion on Days 1, 4 and 7 of Cycle 1 and 2.

Reporting group values	Gemtuzumab Ozogamicin (GO)	Total	
Number of subjects	51	51	
Age Categorical			
Units: subjects			
Age continuous			
Units: years			
arithmetic mean	64.86		
standard deviation	± 11.42	-	
Sex: Female, Male			
Units: subjects			
Female	20	20	
Male	31	31	
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	
Asian	0	0	
Native Hawaiian or Other Pacific Islander	0	0	
Black or African American	3	3	
White	39	39	
More than one race	0	0	
Unknown or Not Reported	9	9	
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	6	6	
Not Hispanic or Latino	40	40	
Unknown or Not Reported	5	5	

End points

End points reporting groups

Reporting group title	Gemtuzumab Ozogamicin (GO)

Reporting group description:

Subjects with confirmed diagnosis of refractory or relapsed cluster of differentiation (CD33)- positive Acute Myeloid Leukemia (AML) aged greater than or equal to (>=) 18 years received three doses of Gemtuzumab Ozogamicin, 3 milligram per meter square (mg/m^2) as intravenous (IV) infusion on Days 1, 4 and 7 of Cycle 1 and 2.

Primary: Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 1: 1 Hour

End point title	Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 1: 1 Hour[1]

End point description:

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate. Change from baseline in QT interval corrected for heart rate using Fridericia's formula was reported. QTc analysis set included all the subjects in the safety analysis set who had a baseline ECG and at least 1 post-dose ECG. Here, 'Number of Subject Analysed' signifies subjects evaluable for this endpoint.

End point type	Primary

End point timeframe:

Baseline, Cycle 1 Day 1: 1 Hour

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	48			
Units: milliseconds				
least squares mean (confidence interval 90%)	4.90 (2.48 to 7.32)			

Statistical analyses

No statistical analyses for this end point

Primary: Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 1: 2 Hours

End point title	Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 1: 2 Hours[2]

End point description:

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate.

Corrected QT interval using Fridericia's heart rate correction formula: QTcF = QT divided by cube root of 60/heart rate. Change from baseline in QT interval corrected for heart rate using Fridericia's formula was reported. QTc analysis set included all the subjects in the safety analysis set who had a baseline ECG and at least 1 post-dose ECG. Here, 'Number of Subject Analysed' signifies subjects evaluable for this endpoint.

End point type	Primary

End point timeframe:

Baseline, Cycle 1 Day 1: 2 Hours

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	46			
Units: milliseconds				
least squares mean (confidence interval 90%)	4.25 (1.66 to 6.84)			

Statistical analyses

No statistical analyses for this end point

Primary: Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 1: 4 Hours

End point title	Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 1: 4 Hours[3]

End point description:

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate. Change from baseline in QT interval corrected for heart rate using Fridericia's formula was reported. QTc analysis set included all the subjects in the safety analysis set who had a baseline ECG and at least 1 post-dose ECG. Here, 'Number of Subject Analysed' signifies subjects evaluable for this endpoint.

End point type	Primary

End point timeframe:

Baseline, Cycle 1 Day 1: 4 Hours

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	49			
Units: milliseconds				
least squares mean (confidence interval 90%)	5.10 (2.15 to 8.06)			

Statistical analyses

No statistical analyses for this end point

Primary: Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 4: 2 Hours

End point title	Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 4: 2 Hours[4]

End point description:

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate. Change from baseline in QT interval corrected for heart rate using Fridericia's formula was reported. QTc analysis set included all the subjects in the safety analysis set who had a baseline ECG and at least 1 post-dose ECG. Here, 'Number of Subject Analysed' signifies subjects evaluable for this endpoint.

End point type	Primary

End point timeframe:

Baseline, Cycle 1 Day 4: 2 Hour

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	46			
Units: milliseconds				
least squares mean (confidence interval 90%)	-0.45 (-3.98 to 3.07)			

Statistical analyses

No statistical analyses for this end point

Primary: Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 4: 0 Hour

End point title	Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 4: 0 Hour[5]

End point description:

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate. Change from baseline in QT interval corrected for heart rate using Fridericia's formula was reported. QTc analysis set included all the subjects in the safety analysis set who had a baseline ECG and at least 1 post-dose ECG. Here, 'Number

of Subject Analysed' signifies subjects evaluable for this endpoint.

End point type	Primary

End point timeframe:

Baseline, Cycle 1 Day 4: 0 Hour

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	47			
Units: milliseconds				
least squares mean (confidence interval 90%)	-2.44 (-5.98 to 1.09)			

Statistical analyses

No statistical analyses for this end point

Primary: Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 7: 2 Hours

End point title	Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 7: 2 Hours[6]

End point description:

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate. Change from baseline in QT interval corrected for heart rate using Fridericia's formula was reported. QTc analysis set included all the subjects in the safety analysis set who had a baseline ECG and at least 1 post-dose ECG. Here, 'Number of Subject Analysed' signifies subjects evaluable for this endpoint.

End point type	Primary

End point timeframe:

Baseline, Cycle 1 Day 7: 2 Hours

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	45			
Units: milliseconds				
least squares mean (confidence interval 90%)	4.29 (0.88 to 7.70)			

Statistical analyses

No statistical analyses for this end point

Primary: Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 7: 0 Hour

End point title	Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 7: 0 Hour[7]

End point description:

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate. Change from baseline in QT interval corrected for heart rate using Fridericia's formula was reported. QTc analysis set included all the subjects in the safety analysis set who had a baseline ECG and at least 1 post-dose ECG. Here, 'Number of Subject Analysed' signifies subjects evaluable for this endpoint.

End point type	Primary

End point timeframe:

Baseline, Cycle 1 Day 7: 0 Hour

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: milliseconds				
least squares mean (confidence interval 90%)	-1.00 (-4.59 to 2.58)			

Statistical analyses

No statistical analyses for this end point

Primary: Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 7: 4 Hours

End point title	Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 7: 4 Hours[8]

End point description:

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate. Change from baseline in QT interval corrected for heart rate using Fridericia's formula was reported. QTc analysis set included all the subjects in the safety analysis set who had a baseline ECG and at least 1 post-dose ECG. Here, 'Number of Subject Analysed' signifies subjects evaluable for this endpoint.

End point type	Primary

End point timeframe:

Baseline, Cycle 1 Day 7: 4 Hours

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: milliseconds				
least squares mean (confidence interval 90%)	4.19 (0.45 to 7.93)			

Statistical analyses

No statistical analyses for this end point

Primary: Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 7: 6 Hours

End point title	Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 7: 6 Hours[9]

End point description:

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate. Change from baseline in QT interval corrected for heart rate using Fridericia's formula was reported. QTc analysis set included all the subjects in the safety analysis set who had a baseline ECG and at least 1 post-dose ECG. Here, 'Number of Subject Analysed' signifies subjects evaluable for this endpoint.

End point type	Primary

End point timeframe:

Baseline, Cycle 1 Day 7: 6 Hours

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	45			
Units: milliseconds				
least squares mean (confidence interval 90%)	1.03 (-2.88 to 4.93)			

Statistical analyses

No statistical analyses for this end point

Primary: Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 2 Day 1: 2 Hours

End point title	Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 2 Day 1: 2 Hours[10]

End point description:

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate. Corrected QT interval using Fridericia's heart rate correction formula: QTcF = QT divided by cube root of 60/heart rate. Change from baseline in QT interval corrected for heart rate using Fridericia's formula was reported. QTc analysis set included all the subjects in the safety analysis set who had a baseline ECG and at least 1 post-dose ECG. Here, 'Number of Subject Analysed' signifies subjects evaluable for this endpoint.

End point type	Primary

End point timeframe:

Baseline, Cycle 2 Day 1: 2 Hours

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: milliseconds				
arithmetic mean (standard deviation)	7.3 (± 9.12)			

Statistical analyses

No statistical analyses for this end point

Primary: Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 2 Day 1: 0 Hour

End point title	Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 2 Day 1: 0 Hour[11]

End point description:

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate. Change from baseline in QT interval corrected for heart rate using Fridericia's formula was reported. QTc analysis set included all the subjects in the safety analysis set who had a baseline ECG and at least 1 post-dose ECG. Here, 'Number of Subject Analysed' signifies subjects evaluable for this endpoint.

End point type	Primary

End point timeframe:

Baseline, Cycle 2 Day 1: 0 Hour

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: milliseconds				
arithmetic mean (standard deviation)	4.0 (± 11.32)			

Statistical analyses

No statistical analyses for this end point

Primary: Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 2 Day 7: 0 Hour

End point title	Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 2 Day 7: 0 Hour[12]

End point description:

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate. Change from baseline in QT interval corrected for heart rate using Fridericia's formula was reported. QTc analysis set included all the subjects in the safety analysis set who had a baseline ECG and at least 1 post-dose ECG. Here, 'Number of Subject Analysed' signifies subjects evaluable for this endpoint.

End point type	Primary

End point timeframe:

Baseline, Cycle 2 Day 7: 0 Hour

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: milliseconds				
arithmetic mean (standard deviation)	-5.4 (± 7.58)			

Statistical analyses

No statistical analyses for this end point

Primary: Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 2 Day 7: 2 Hours

End point title	Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 2 Day 7: 2 Hours[13]

End point description:

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. QT interval was the time between the start of the Q wave and

the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate. Change from baseline in QT interval corrected for heart rate using Fridericia's formula was reported. QTc analysis set included all the subjects in the safety analysis set who had a baseline ECG and at least 1 post-dose ECG. Here, 'Number of Subject Analysed' signifies subjects evaluable for this endpoint.

End point type	Primary

End point timeframe:

Baseline, Cycle 2 Day 7: 2 Hours

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: milliseconds				
arithmetic mean (standard deviation)	-1.6 (± 10.69)			

Statistical analyses

No statistical analyses for this end point

Primary: Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 2 Day 7: 6 Hours

End point title	Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 2 Day 7: 6 Hours[14]

End point description:

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate. Change from baseline in QT interval corrected for heart rate using Fridericia's formula was reported. QTc analysis set included all the subjects in the safety analysis set who had a baseline ECG and at least 1 post-dose ECG. Here, 'Number of Subject Analysed' signifies subjects evaluable for this endpoint.

End point type	Primary

End point timeframe:

Baseline, Cycle 2 Day 7: 6 Hours

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: milliseconds				
arithmetic mean (standard deviation)	-8.8 (± 14.43)			

Statistical analyses

No statistical analyses for this end point

Secondary: Clearance (CL) of Gemtuzumab Ozogamicin

End point title	Clearance (CL) of Gemtuzumab Ozogamicin

End point description:

Clearance of a drug was measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Pharmacokinetic (PK) analysis set included all subjects who were treated with GO and contributed at least 1 PK sample. Here, 'n' = subjects evaluable for this endpoint for specified rows.

End point type	Secondary

End point timeframe:

Pre dose, 2, 4, 6, 72, 192 and 336 hours post dose on Cycle 1 Day 7

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: Liters/hour				
geometric mean (geometric coefficient of variation)				
AC-CL-184538 (n=47)	15.02 (± 112)			
CL-184538 (n=45)	4246 (± 177)			
Total HP67.6 Antibody (n=47)	0.3212 (± 153)			

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Observed Plasma Concentration (Cmax): AC-CL-184538 and CL-184538

End point title	Maximum Observed Plasma Concentration (Cmax): AC-CL-184538 and CL-184538

End point description:

Cmax was defined as the maximum observed plasma concentration of GO. Calicheamicin (conjugated calicheamicin ac-CL-184538 and unconjugated CL-184538) analyte were used to determined the Cmax in this endpoint. PK analysis set included all the subjects who were treated with GO and contributed at least 1 PK sample. Here, 'n' = subjects evaluable for this endpoint at specific time point.

End point type	Secondary

End point timeframe:

Pre dose, 1, 2, 4, 6, 24 and 72 hours post dose on Cycle 1 Day 1; and Pre dose, 2, 4, 6, 72, 192 and 336 hours post dose on Cycle 1 Day 7

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: picogram/milliliter				
geometric mean (geometric coefficient of variation)				
Cycle 1 Day 1: AC-CL-184538, (n=50)	6457 (± 81)			
Cycle 1 Day 1: CL-184538, (n=50)	45.69 (± 51)			
Cycle 1 Day 7: AC-CL-184538, (n=47)	11740 (± 79)			
Cycle 1 Day 7: CL-184538, (n=47)	58.76 (± 70)			

Statistical analyses

No statistical analyses for this end point

Secondary: Volume of Distribution of Gemtuzumab Ozogamicin

End point title	Volume of Distribution of Gemtuzumab Ozogamicin

End point description:

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

End point type	Secondary

End point timeframe:

Pre dose, 2, 4, 6, 72, 192 and 336 hours post dose on Cycle 1 Day 7

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	0[15]			
Units: Liters				
geometric mean (geometric coefficient of variation)	()			

Notes:

[15] - Endpoint not estimated due to insufficient concentration-time data by non-compartmental analysis.

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Observed Plasma Concentration (Cmax): Total HP67.6 Antibody

End point title	Maximum Observed Plasma Concentration (Cmax): Total HP67.6 Antibody

End point description:

Cmax was defined as the maximum observed plasma concentration of GO. Total HP67.6 antibodies analyte was used to determined the Cmax in this endpoint. PK analysis set included all the subjects who were treated with GO and contributed at least 1 PK sample. Here, 'n' = subjects evaluable for this endpoint at specific time point.

End point type	Secondary

End point timeframe:

Pre dose, 1, 2, 4, 6, 24 and 72 hours post dose on Cycle 1 Day 1; and Pre dose, 2, 4, 6, 72, 192 and 336 hours post dose on Cycle 1 Day 7

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: nanogram/milliliter				
geometric mean (geometric coefficient of variation)				
Cycle 1 Day 1: Total HP67.6 Antibody, (n=50)	282.1 (± 77)			
Cycle 1 Day 7: Total HP67.6 Antibody, (n=47)	585.6 (± 105)			

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Reach Maximum Observed Plasma Concentration (Tmax)

End point title	Time to Reach Maximum Observed Plasma Concentration (Tmax)

End point description:

Tmax = time (hours) to reach maximum plasma concentration (Cmax). PK analysis set included all the subjects who were treated with GO and contributed at least 1 PK sample. Here, 'n' = subjects evaluable for this endpoint at specific time point.

End point type	Secondary

End point timeframe:

Pre dose, 1, 2, 4, 6, 24 and 72 hours post dose on Cycle 1 Day 1; and Pre dose, 2, 4, 6, 72, 192 and 336 hours post dose on Cycle 1 Day 7

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: hours				
median (full range (min-max))				
Cycle 1 Day 1: AC-CL-184538, (n=50)	2.080 (0.933 to 5.83)			

Cycle 1 Day 1: CL-184538, (n=41)	2.170 (1.00 to 6.08)				
Cycle 1 Day 1: Total HP67.6 Antibody, (n=49)	2.080 (0.933 to 4.25)				
Cycle 1 Day 7: AC-CL-184538, (n=47)	2.130 (0.000 to 6.25)				
Cycle 1 Day 7: CL-184538, (n=45)	3.920 (1.85 to 6.10)				
Cycle 1 Day 7: Total HP67.6 Antibody, (n=47)	2.170 (1.92 to 6.40)				

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Plasma Concentration-time Profile From Time Zero to the Time of Last Quantifiable Concentration (AUClast): AC-CL-184538 and CL-184538

End point title	Area Under the Plasma Concentration-time Profile From Time Zero to the Time of Last Quantifiable Concentration (AUClast): AC-CL-184538 and CL-184538

End point description:

Area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUClast). Calicheamicin (conjugated calicheamicin ac-CL-184538 and unconjugated CL-184538) analytes were used to determined the AUClast in this endpoint. PK analysis set included all the subjects who were treated with GO and contributed at least 1 PK sample. Here, 'n' = subjects evaluable for this endpoint at specific time point.

End point type	Secondary

End point timeframe:

Pre dose, 1, 2, 4, 6, 24 and 72 hours post dose on Cycle 1 Day 1; and Pre dose, 2, 4, 6, 72, 192 and 336 hours post dose on Cycle 1 Day 7

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: picogram*hour/milliliter				
geometric mean (geometric coefficient of variation)				
Cycle 1 Day 1: AC-CL-184538, (n=50)	93260 (± 83)			
Cycle 1 Day 1: CL-184538, (n=50)	99.83 (± 171)			
Cycle 1 Day 7: AC-CL-184538, (n=47)	453900 (± 120)			
Cycle 1 Day 7: CL-184538, (n=47)	242.0 (± 283)			

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Plasma Concentration-time Profile From Time Zero to the Time of Last Quantifiable Concentration (AUClast): Total HP67.6 Antibody

End point title	Area Under the Plasma Concentration-time Profile From Time Zero to the Time of Last Quantifiable Concentration (AUClast): Total HP67.6 Antibody

End point description:

Area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUClast). Total HP67.6 antibodies analyte was used to determined the AUClast in this endpoint. PK analysis set included all the subjects who were treated with GO and contributed at least 1 PK sample. Here, 'n' = subjects evaluable for this endpoint at specific time point.

End point type	Secondary

End point timeframe:

Pre dose, 1, 2, 4, 6, 24 and 72 hours post dose on Cycle 1 Day 1; and Pre dose, 2, 4, 6, 72, 192 and 336 hours post dose on Cycle 1 Day 7

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: nanogram*hour/milliliter				
geometric mean (geometric coefficient of variation)				
Cycle 1 Day 1: Total HP67.6 Antibody, (n=50)	2496 (± 210)			
Cycle 1 Day 7: Total HP67.6 Antibody, (n=47)	14740 (± 388)			

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Plasma Concentration-time Profile From Time Zero to Time 72 Hours (AUC0-72): AC-CL-184538 and CL-184538

End point title	Area Under the Plasma Concentration-time Profile From Time Zero to Time 72 Hours (AUC0-72): AC-CL-184538 and CL-184538

End point description:

Area under the plasma concentration-time curve from time zero to the time 72 hours (AUC0-72). Calicheamicin (conjugated calicheamicin ac-CL-184538 and unconjugated CL-184538) analytes were used to determined the AUC0-72 in this endpoint. PK analysis set included all the subjects who were treated with GO and contributed at least 1 PK sample. Here, 'n' = subjects evaluable for this endpoint for specified rows.

End point type	Secondary

End point timeframe:

Pre dose, 1, 2, 4, 6, 24 and 72 hours post dose on Cycle 1 Day 1

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: picogram*hour/milliliter				
geometric mean (geometric coefficient of variation)				
AC-CL-184538, (n=50)	93490 (± 82)			
CL-184538, (n=36)	247.8 (± 176)			

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Plasma Concentration-time Profile From Time Zero to Time 72 Hours (AUC0-72): Total HP67.6 Antibody

End point title	Area Under the Plasma Concentration-time Profile From Time Zero to Time 72 Hours (AUC0-72): Total HP67.6 Antibody
End point description:	

Area under the plasma concentration-time curve from time zero to the time 72 hours (AUC0-72). Total HP67.6 antibodies analyte was used to determined the AUC0-72 in this endpoint. PK analysis set included all the subjects who were treated with GO and contributed at least 1 PK sample. Here, 'Number of Subject Analysed' signifies subjects evaluable for this endpoint.

End point type	Secondary
End point timeframe:	

Pre dose, 1, 2, 4, 6, 24 and 72 hours post dose on Cycle 1 Day 1

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	48			
Units: nanogram*hour/milliliter				
geometric mean (geometric coefficient of variation)	3797 (± 135)			

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Plasma Concentration-time Profile From Time Zero to Time 336 Hours (AUC0-336): AC-CL-184538 and CL-184538

End point title	Area Under the Plasma Concentration-time Profile From Time Zero to Time 336 Hours (AUC0-336): AC-CL-184538 and CL-184538
End point description:	

Area under the plasma concentration-time curve from time zero to the time 336 hours (AUC0-336).

Calicheamicin (conjugated calicheamicin ac-CL-184538 and unconjugated CL-184538) analytes were used to determined the AUC0-336 in this endpoint. PK analysis set included all the subjects who were treated with GO and contributed at least 1 PK sample. Here, 'n' = subjects evaluable for this endpoint for specified rows.

End point type	Secondary

End point timeframe:

Pre dose, 2, 4, 6, 72, 192 and 336 hours post dose on Cycle 1 Day 7

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: picogram*hour/milliliter				
geometric mean (geometric coefficient of variation)				
AC-CL-184538, (n=45)	461500 (± 121)			
CL-184538, (n=35)	1639 (± 181)			

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Plasma Concentration-time Profile From Time Zero to Time 336 Hours (AUC0-336): Total HP67.6 Antibody

End point title	Area Under the Plasma Concentration-time Profile From Time Zero to Time 336 Hours (AUC0-336): Total HP67.6 Antibody

End point description:

Area under the plasma concentration-time curve from time zero to the time 336 hours (AUC0-336). Total HP67.6 antibodies analyte was used to determined the AUC0-336 in this endpoint. PK analysis set included all the subjects who were treated with GO and contributed at least 1 PK sample. Here, 'Number of Subject Analysed' signifies subjects evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Pre dose, 2, 4, 6, 72, 192 and 336 hours post dose on Cycle 1 Day 7

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	42			
Units: nanogram*hour/milliliter				
geometric mean (geometric coefficient of variation)	26820 (± 131)			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

End point title	Number of Subjects With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

End point description:

An AE was any untoward medical occurrence in a subject who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalisation; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event between first dose of study drug and up to 36 days after the last dose of study drug, that was absent before treatment, or that worsened during the treatment period relative to the pretreatment state. AEs included all serious and non-serious adverse events. Safety analysis set included all enrolled subjects who received at least 1 dose of study medication.

End point type	Secondary

End point timeframe:

From first dose of study drug up to 36 days after last dose (up to a maximum of 12 months)

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: subjects				
TEAEs	49			
SAEs	34			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Shift From Grade <=2 at Baseline to Grade 3 or 4 Post-Baseline in Clinical Laboratory Abnormalities- Hematology and Coagulation Parameters

End point title	Number of Subjects With Shift From Grade <=2 at Baseline to Grade 3 or 4 Post-Baseline in Clinical Laboratory Abnormalities-Hematology and Coagulation Parameters

End point description:

Laboratory parameters included hematological and coagulation parameters. These included activated partial thromboplastin time prolonged, anemia, fibrinogen decreased, hemoglobin increased, international normalized ratio increased, leukocytosis, lymphocyte count decreased, lymphocyte count

increased, neutrophil count decreased, platelet count decreased, white blood cell decreased. Number of subjects with hematological and coagulation abnormalities by grades (as per Common Terminology Criteria for Adverse Events (CTCAE version 4.03) were reported. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Safety analysis set included all enrolled subjects who received at least 1 dose of study medication.

End point type	Secondary

End point timeframe:

From first dose of study drug up to 36 days after last dose (up to a maximum of 12 months)

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: subjects	43			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Positive Anti-Drug Antibody (ADA)

End point title	Percentage of Subjects With Positive Anti-Drug Antibody (ADA)

End point description:

Percentage of subjects with treatment-induced ADA positive (post baseline-positive only) and treatment-boosted ADA positive (baseline ADA titer that was boosted to a 9-fold or higher level following drug administration) were reported in this endpoint. Immunogenicity analysis set included all subjects in the safety analysis set who had at least 1 immunogenicity sample with results.

End point type	Secondary

End point timeframe:

From first dose of study drug up to maximum of 12 months

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: percentage of subjects				
number (not applicable)				
Treatment-induced ADA Positive	12.0			
Treatment-boosted ADA Positive	0.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Shift From Grade <=2 at Baseline to Grade 3 or 4 Post-Baseline in Clinical Laboratory Abnormalities- Chemistry Parameters

End point title	Number of Subjects With Shift From Grade <=2 at Baseline to Grade 3 or 4 Post-Baseline in Clinical Laboratory Abnormalities- Chemistry Parameters

End point description:

Laboratory parameters included chemistry parameters. These included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, and hyponatremia. Number of subjects with chemistry test abnormalities by grades (CTCAE version 4.03) were reported. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Safety analysis set included all enrolled subjects who received at least 1 dose of study medication.

End point type	Secondary

End point timeframe:

From first dose of study drug up to 36 days after last dose (up to a maximum of 12 months)

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: subjects	18			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Positive Neutralizing Antibodies (NAb)

End point title	Percentage of Subjects With Positive Neutralizing Antibodies (NAb)

End point description:

Percentage of subjects who had post baseline positive ADA response were evaluated for NAb. Immunogenicity analysis set included all subjects in the safety analysis set who had at least 1 immunogenicity sample with results.

End point type	Secondary

End point timeframe:

From first dose of study drug up to maximum of 12 months

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: percentage of subjects				
number (not applicable)	2.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects who Achieved Complete Remission (CR) and Complete Remission With Incomplete Hematologic Recovery (CRi)

End point title	Percentage of Subjects who Achieved Complete Remission (CR) and Complete Remission With Incomplete Hematologic Recovery (CRi)

End point description:

Percentage of subjects with first dose of study drug to best overall response with CR and CRi were reported. CR was defined as the disappearance of leukemia indicated by less than (<) 5 percent (%) bone marrow blasts, absence of circulating blasts with Auer rods and absence of extramedullary disease, with recovery of hematopoiesis defined by absolute neutrophil count (ANC) greater than or equal to (>=)1000 per microliter (1000/mcL) and platelets >=100,000/mcL. CRi was defined as all CR criteria except residual neutropenia; ANC <1000/mcL or thrombocytopenia and platelet count <100,000/mcL. Full analysis set included all enrolled subjects.

End point type	Secondary

End point timeframe:

From first dose of study drug to 36 days after last dose (maximum up to of 12 months)

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	51			
Units: percentage of subjects				
number (confidence interval 95%)				
CR+CRi	9.8 (3.3 to 21.4)			

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)

End point description:

OS was defined as the time (in months) from the start date (first dose) of study treatment to the date of death due to any cause. Subjects last known to be alive were censored at date of last contact. Analysis

was performed using Kaplan-Meier method. Full analysis set included all enrolled subjects

End point type	Secondary

End point timeframe:

From the first dose of study treatment to the date of death or date of censored, whichever occurred first (maximum up to 12 months)

End point values	Gemtuzumab Ozogamicin (GO)			
Subject group type	Reporting group			
Number of subjects analysed	51			
Units: months				
median (confidence interval 95%)	2.8 (1.7 to 4.2)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:	
From first dose of study drug up to 36 days after last dose (up to a maximum of 12 months)	
Adverse event reporting additional description:	
Same event may appear as AE and serious AE, what is presented are distinct events. Event may be categorized as serious in 1 subject and as non-serious in another subject or 1 subject may have experienced both serious and non-serious event during study. Safety analysis set analysed.	
Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	24.0

Reporting groups

Reporting group title	Gemtuzumab Ozogamicin (GO)
Reporting group description:	
Subjects with confirmed diagnosis of refractory or relapsed CD33-positive Acute Myeloid Leukemia (AML) aged >= 18 years received three doses of Gemtuzumab Ozogamicin, 3 mg/m^2 as IV infusion on Days 1, 4 and 7 of Cycle 1 and 2.	

Serious adverse events	Gemtuzumab Ozogamicin (GO)		
Total subjects affected by serious adverse events			
subjects affected / exposed	34 / 50 (68.00%)		
number of deaths (all causes)	45		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute Myeloid Leukaemia			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Traumatic Intracranial Haemorrhage			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Fall			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Vascular disorders			
Capillary Leak Syndrome			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	1 / 1		
Cardiac disorders			
Atrial Fibrillation			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Supraventricular Tachycardia			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Febrile Neutropenia			
subjects affected / exposed	11 / 50 (22.00%)		
occurrences causally related to treatment / all	3 / 12		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia			
subjects affected / exposed	2 / 50 (4.00%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
Anaemia			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Disease Progression			
subjects affected / exposed	5 / 50 (10.00%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 0		
Pyrexia			

subjects affected / exposed	3 / 50 (6.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 1		
Multiple Organ Dysfunction Syndrome			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Eye disorders			
Vitreous Floaters			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Gastric Haemorrhage			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Respiratory Failure			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Infections and infestations			
Pneumonia			
subjects affected / exposed	3 / 50 (6.00%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	7 / 50 (14.00%)		
occurrences causally related to treatment / all	0 / 10		
deaths causally related to treatment / all	0 / 4		
Atypical Pneumonia			

subjects affected / exposed	2 / 50 (4.00%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 1		
Covid-19 Pneumonia			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Escherichia Urinary Tract Infection			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Eye Infection Fungal			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neutropenic Sepsis			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia Klebsiella			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia Respiratory Syncytial Viral			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sinusitis			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			

subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Gemtuzumab Ozogamicin (GO)		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	36 / 50 (72.00%)		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	4 / 50 (8.00%)		
occurrences (all)	6		
Aspartate aminotransferase increased			
subjects affected / exposed	5 / 50 (10.00%)		
occurrences (all)	7		
Gamma-glutamyltransferase increased			
subjects affected / exposed	3 / 50 (6.00%)		
occurrences (all)	4		
Injury, poisoning and procedural complications			
Infusion related reaction			
subjects affected / exposed	3 / 50 (6.00%)		
occurrences (all)	3		
Nervous system disorders			
Headache			
subjects affected / exposed	5 / 50 (10.00%)		
occurrences (all)	6		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	5 / 50 (10.00%)		
occurrences (all)	6		
Febrile neutropenia			
subjects affected / exposed	9 / 50 (18.00%)		
occurrences (all)	10		
Neutropenia			

subjects affected / exposed	5 / 50 (10.00%)		
occurrences (all)	10		
Thrombocytopenia			
subjects affected / exposed	9 / 50 (18.00%)		
occurrences (all)	20		

General disorders and administration site conditions

Asthenia			
subjects affected / exposed	3 / 50 (6.00%)		
occurrences (all)	3		
Fatigue			
subjects affected / exposed	4 / 50 (8.00%)		
occurrences (all)	6		
Pyrexia			
subjects affected / exposed	6 / 50 (12.00%)		
occurrences (all)	7		

Gastrointestinal disorders

Abdominal pain upper			
subjects affected / exposed	3 / 50 (6.00%)		
occurrences (all)	3		
Constipation			
subjects affected / exposed	5 / 50 (10.00%)		
occurrences (all)	5		
Diarrhoea			
subjects affected / exposed	5 / 50 (10.00%)		
occurrences (all)	5		
Vomiting			
subjects affected / exposed	6 / 50 (12.00%)		
occurrences (all)	6		
Nausea			
subjects affected / exposed	8 / 50 (16.00%)		
occurrences (all)	9		
Gingival bleeding			
subjects affected / exposed	3 / 50 (6.00%)		
occurrences (all)	3		

Respiratory, thoracic and mediastinal disorders

Epistaxis			
subjects affected / exposed	5 / 50 (10.00%)		
occurrences (all)	5		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	3 / 50 (6.00%)		
occurrences (all)	3		
Metabolism and nutrition disorders			
Hypokalaemia			
subjects affected / exposed	9 / 50 (18.00%)		
occurrences (all)	17		
Hypomagnesaemia			
subjects affected / exposed	5 / 50 (10.00%)		
occurrences (all)	8		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol?   No

---

Interruptions (globally)

Were there any global interruptions to the trial?   No

Limitations and caveats

 None reported